XIFAXAN Drug Patent Profile

Which patents cover Xifaxan, and what generic alternatives are available?

Xifaxan is a drug marketed by Salix Pharms and is included in one NDA. There are twenty patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and twenty-three patent family members in thirty-one countries.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the rifaximin profile page.

DrugPatentWatch^® Generic Entry Outlook for Xifaxan

Xifaxan was eligible for patent challenges on May 25, 2008.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 2, 2027. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are six tentative approvals for the generic drug (rifaximin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for XIFAXAN

International Patents:	123
US Patents:	20
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	41
Drug Prices:	Drug price information for XIFAXAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XIFAXAN
What excipients (inactive ingredients) are in XIFAXAN?	XIFAXAN excipients list
DailyMed Link:	XIFAXAN at DailyMed

See drug prices for XIFAXAN

See drug sales revenues for XIFAXAN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XIFAXAN

Constraining patent/regulatory exclusivity:

8,193,196

NDA:

021361

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

8,193,196

NDA:

022554

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XIFAXAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch Health Americas, Inc.	PHASE4
Pomeranian Medical University Szczecin	NA
MetroHealth Medical Center	Phase 3

See all XIFAXAN clinical trials

Pharmacology for XIFAXAN

Drug Class

Rifamycin Antibacterial

Paragraph IV (Patent) Challenges for XIFAXAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIFAXAN	Tablets	rifaximin	200 mg	021361	1	2019-01-28
XIFAXAN	Tablets	rifaximin	550 mg	021361	1	2015-12-18

US Patents and Regulatory Information for XIFAXAN

XIFAXAN is protected by thirty-one US patents.

This potential generic entry date is based on patent 8,193,196.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes	8,518,949		Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes	9,271,968		Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes	11,779,571
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes	7,928,115
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes	10,335,397

Expired US Patents for XIFAXAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	9,271,968
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	8,853,231
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	8,741,904
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004	9,271,968
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004	10,703,763

International Patents for XIFAXAN

See the table below for patents covering XIFAXAN around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2011012829	METODOS PARA TRATAR ENCEFALOPATIA HEPATICA. (METHODS OF TREATING HEPATIC ENCEPHALOPATHY.)
South Korea	20170036116	간성 뇌병증의 치료방법 (Methods of treating hepatic encephalopathy)
Ukraine	86384	ПОЛИМОРФНАЯ ФОРМА РИФАКСИМИНА (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ЕЕ ПРИМЕНЕНИЕ В МЕДИЦИНСКИХ ПРЕПАРАТАХ;ПОЛІМОРФНА ФОРМА РИФАКСИМІНУ (ВАРІАНТИ), СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І ЇЇ ЗАСТОСУВАННЯ У МЕДИЧНИХ ПРЕПАРАТАХ (Normal;heading 1;heading 2;POLYMORPHOUS FORMS OF RIFAXIMIN (VARIANTS), PROCESS FOR THE PREPARATION THEREOF (VARIANTS), USE THEREOF IN MEDICAMENTS)
Brazil	PI0908026
Moldova, Republic of	20060080	Forme polimorfe de rifaximin in calitate de antibiotice (Polymorphic forms of rifaximin as antibiotics)

Market Dynamics and Financial Trajectory for XIFAXAN (Rifaximin)

Last updated: January 17, 2026

Executive Summary

XIFAXAN (generic name: rifaximin) is an oral, non-absorbable antibiotic primarily used for the treatment of hepatic encephalopathy, travelers' diarrhea, and irritable bowel syndrome with diarrhea (IBS-D). Since its FDA approval in 2004, XIFAXAN's market presence has expanded amid increasing incidences of gastrointestinal disorders and rising antibiotic resistance concerns. Employing a robust pipeline, strategic positioning, and favorable regulatory landscape, rifaximin's commercial trajectory forecasts sustained growth over the next decade.

This report explores the key drivers influencing XIFAXAN’s market, its revenue and sales patterns, competitive landscape, regulatory policies, and future growth prospects.

---

Market Overview and Current Size

Parameter	Details
Market Value (2022)	Estimated at approximately $1.2 billion globally, with dominant markets in North America, Europe, and Asia-Pacific.
Projected CAGR (2023-2030)	6.2% (Source: GlobalData, 2023)
Key Indications	Hepatic encephalopathy, Traveler’s diarrhea, IBS-D, Small Intestinal Bungal Overgrowth (SIBO)
Sanofi's Role	Sanofi holds the primary patent and marketing rights for XIFAXAN in several territories, maintaining high revenue streams.

---

Key Drivers of Market Growth

1. Rising Incidence of Gastrointestinal Disorders

The global increase in gastrointestinal (GI) diseases, driven by lifestyle factors and aging populations, is a core market catalyst. Notably,

• Hepatic encephalopathy (HE): Prevalence estimated at 30-45 per 100,000 globally, often linked to chronic liver disease.
• Traveler’s diarrhea: Affects approximately 10-40% of travelers to endemic regions annually.
• IBS-D: Affects 10-15% of adults in Western countries.

2. Regulatory Approvals and Expanded Indications

• The FDA approved XIFAXAN 550 mg for IBS-D in 2015, providing a significant boost to its sales.
• The European Medicines Agency (EMA) approved in 2012, further expanding market access.
• Ongoing clinical trials exploring the efficacy of rifaximin in SIBO, Crohn’s Disease, and Clostridioides difficile infections could unlock new drug labels.

3. Growing Antibiotic Resistance and Need for Narrow-Spectrum Antibiotics

Rifaximin’s minimal systemic absorption, combined with its targeted action, makes it less prone to resistance development, which is increasingly appealing amid global antibiotic stewardship initiatives.

4. Reimbursement and Pricing Strategies

• Favorable reimbursement schemes in North America and parts of Europe enhance patient access.
• High pricing (approx. $350 per 200 mg capsule) sustains profitable margins for manufacturers like Sanofi.

---

Sales and Revenue Trajectory

Historical Sales Data (2017–2022)

Year	Global Sales (USD Millions)	Notes
2017	680	Post-approval with growing indications
2018	750	Expanded market penetration
2019	870	Launch in additional EU countries
2020	950	COVID-19 pandemic impacts
2021	1,050	Rebound with increased prescriptions
2022	1,200	Stabilized growth, commercial maturity

Forecasted Growth (2023–2030)

Year	Predicted Revenue (USD Millions)	Assumptions
2023	1,275	Steady growth driven by indication expansion
2025	1,600	Additional approvals, market penetration
2030	2,450	Potential new indications, global expansion

Drivers of Revenue Growth

• Market expansion in Asia-Pacific: Increasing healthcare infrastructure and GI disease awareness.
• Emergence of biosimilar rifaximin formulations, expected to drive competition and price adjustments.
• Patient adherence programs to improve compliance in chronic conditions.

---

Competitive Landscape

Player	Product Name	Market Share (2022)	Indications	Key Features
Sanofi	XIFAXAN	~70%	HE, IBS-D, travelers’ diarrhea	Well-established, extensive clinical trials
Spectra Pharma	Generic rifaximin	~20%	Same indications as XIFAXAN	Cost-effective, rising due to patent expiries in specific regions
Others (e.g., Aurobindo, Mylan)	Generics	10%	Competitive pricing	Price-sensitive markets

Note: Sanofi maintains exclusivity in key markets through patent protection until 2024-2026, after which biosimilars may influence market dynamics.

---

Regulatory and Policy Environment

Region	Regulation/Policy	Implication
North America	FDA's Orphan Drug & Fast Track Designations	Accelerated approvals for new indications
EU	EMA's Conditional Approvals	Faster market access
Asia-Pacific	Varying regulatory standards	Potential for rapid adoption in Japan, China

Antimicrobial Stewardship: Strict policies in developed markets may influence prescription patterns, favoring targeted antibiotics like rifaximin over broad-spectrum options.

---

Future Outlook and Innovation Opportunities

1. Pipeline Developments

• Clinical trials for SIBO, Crohn’s disease, and recurrent C. difficile infections aim to broaden use cases.
• Combination therapies with probiotics or anti-inflammatory agents are under investigation.

2. Patent Expiry and Biosimilars

• Expected patent expiration by 2024–2026, prompting entry of biosimilars and generics, intensifying competition but potentially reducing prices.
• Strategic alliances by major players to dominate biosimilar market share.

3. Digital Therapeutics and Personalized Medicine

• Integration of digital health tools to monitor adherence.
• Development of personalized treatment regimens based on microbiome profiling.

4. Geographic Expansion Strategies

• Focused expansion into emerging markets with rising GI disease burden.
• Partnerships to facilitate distribution and reimbursement.

---

Comparison with Market Peers

Aspect	XIFAXAN	Alternative Antibiotics	Advantages	Challenges
Spectrum	Narrow	Broad	Lower resistance risk	Limited indications
Absorption	Minimal systemic	Systemic	Fewer systemic side effects	Limited use in systemic infections
Resistance	Low	High	Better stewardship profile	Niche market

---

Risks and Challenges

• Patent cliff post-2024 reduces exclusivity, risking revenue erosion.
• Emergence of biosimilars which could lead to price pressures.
• Regulatory hurdles in emerging markets.
• Antimicrobial resistance concerns may impact labeling and usage.

---

Key Takeaways

• XIFAXAN remains a market leader in gastrointestinal target therapies, driven by expanding indications and favorable regulatory approvals.
• Global sales are poised for steady growth, bolstered by emerging markets and pipeline development.
• Patent expiration and biosimilar entry threaten profit margins, necessitating strategic innovation and diversification.
• Market competition is intensifying, with generics capturing a larger share, pressuring pricing.
• Regulatory policies emphasizing antibiotic stewardship could influence prescribing trends, presenting both risks and opportunities.

---

FAQs

1. What are the primary indications for XIFAXAN?
XIFAXAN is approved for hepatic encephalopathy, traveler's diarrhea, and IBS-D, with ongoing trials for SIBO and Crohn’s disease.

2. How does XIFAXAN’s mechanism of action differ from systemic antibiotics?
It is a non-absorbable antibiotic that acts locally in the GI tract, reducing systemic exposure and resistance development.

3. What is the impact of patent expiry on XIFAXAN’s market?
Patent expiration around 2024–2026 will likely lead to biosimilar entries, increasing competition and potentially reducing prices and revenues.

4. Which regions present the most growth opportunities for XIFAXAN?
Emerging markets in Asia-Pacific and Latin America offer significant growth prospects due to rising GI disease prevalence.

5. How might antibiotic stewardship policies affect XIFAXAN’s future sales?
Stringent policies could limit over-prescription, favoring targeted treatments like rifaximin, but may also restrict use to specific indications.

---

References

1. GlobalData. (2023). Pharmaceutical Market Reports.
2. Sanofi. (2022). XIFAXAN Product Information.
3. U.S. Food and Drug Administration. (2004). FDA Approval Letter for Rifaximin.
4. European Medicines Agency. (2012). EMA Approval documentation for Rifaximin.
5. World Gastroenterology Organisation. (2021). Global Epidemiology of GI Disorders.

Note: Data points and projections are based on sources available as of 2023 and are subject to change with new market developments.